Pfizer Inc. (NYSE:PFE) Shares Sold by TrueMark Investments LLC

TrueMark Investments LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 15.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 108,970 shares of the biopharmaceutical company’s stock after selling 20,502 shares during the quarter. TrueMark Investments LLC’s holdings in Pfizer were worth $2,891,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Financial Engines Advisors L.L.C. acquired a new stake in Pfizer during the 4th quarter worth about $384,000. Summitry LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $228,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $235,000. Meiji Yasuda Asset Management Co Ltd. boosted its stake in Pfizer by 1.6% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 194,055 shares of the biopharmaceutical company’s stock worth $5,148,000 after purchasing an additional 2,974 shares during the period. Finally, PKS Advisory Services LLC purchased a new position in Pfizer during the 4th quarter worth approximately $324,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Down 2.2 %

Shares of PFE stock opened at $25.56 on Wednesday. The business’s 50 day moving average is $26.14 and its two-hundred day moving average is $27.00. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market cap of $144.96 billion, a PE ratio of 18.13, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The business’s quarterly revenue was up 24.7% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.